… revenue will propel innovation, the costs are stoking patients’ distress and creating a rift between manufacturers, health authorities and payers in many markets. Take the new lung-cancer drugs from Merck & Co., Bristol-Myers Squibb Co. and Roche …
Category: Business News
Directors Guild Denies Violating Obamacare
… medicine and avoided surgeries, but according to the lawsuit, he was told in October 2014 that the DGA Producer Health Plan wouldn’t pay for naturopathic care. He and Grossman claim that the refusal of coverage violates the Affordable Care Act’s …
3 Under-the-Radar Biotech Stocks to Watch in 2017
… test for colorectal cancer is winning buy-in from more payers. As of Jan. 1, 2017, the test will be covered by health plans with over 153 million members. That’s a huge jump of more than 50 million covered members from just six months ago. Exact …
In an Ironic Twist, Obamacare Enrollment Hits an All-Time High
… demise, Obamacare enrollment is currently proceeding at a record pace, at least according to the Department of Health and Human Services. According to the HHS, roughly 6.4 million people had enrolled via HealthCare.gov, the federally run website …
3 Myths About Marijuana Stocks
What do Hercules, Thor, centaurs, and marijuana stocks have in common? They’re all the subjects of myths. Most myths have at least a little bit of truth interspersed with a lot that is false.
California’s Gigantic Medical-Marijuana Industry Could Be Devastated by an Unlikely Source
If you support the legalization of marijuana, 2016 didn’t give you much to complain about. Last year, residents in four states approved recreational-marijuana ballot initiatives, doubling the total from the end of 2015, while five new states put medical-cannabis laws on their books.
4 Financial Surprises Awaiting Seniors in 2017
The stock market has been exploring all-time highs since the election, the U.S. unemployment rate is at a nine-year low of 4.6%, and U.S. GDP growth in the third quarter came in at 3.5%, its most robust growth rate in two years. By all accounts, there’s plenty of reason for investors and working Americans to be excited for what 2017 might bring.
Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals
Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals In 2016, these two stocks have taken paths as varied as their approaches to drug development, and the past few months have been a wild ride.
The 5 Best Stocks in the Dow Jones in 2016
… is the outlier among this group, having seen quite strong performance for two years in a row. For the most part, the health-insurance giant has navigated changing conditions in the industry quite well, adapting to reform efforts and finding …
Aetna Fight for Humana Awaits Court Ruling in U.S. Merger Case
Aetna Inc.’s fight to complete it purchase of Humana Inc. is now with a federal judge who must decide whether the combination of the two health insurers should be blocked because it risks raising costs for consumers. U.S. District Judge John D. Bates in Washington heard final arguments Friday from the companies and the Justice Department about the $37 billion deal, which the government says should be stopped.
Apollo Endosurgery Shares Up 20% After Going Public With Reverse Merger
Austin, Texas-based Apollo focuses on less-invasive therapies for the treatment of obesity and gastrointestinal disorders. Its investors include affiliates of PTV Healthcare Capital, H.I.G. BioHealth Partners, Remeditex Ventures, Novo A/S and CPMG Inc. Apollo’s deal to merge with San Diego, Calif.-based Lpath, which develops lipidomic-based therapeutic antibodies, was first announced Sept.
article
… and Opko’s longer-lasting candidate might have performed even better with a more convenient dosing schedule. Opko Health isn’t throwing in the towel just yet. Although hGH-CTP failed to significantly reduce trunk fat mass compared to a placebo after …
How Risky Is Altria Group, Inc.?
… and have limited borrowing capacity. As a result, taxing tobacco is a fertile source of revenue. Moreover, with health advocates calling for measures to reduce smoking and encourage smokers to quit, tobacco taxes are often politically attractive as …
Biotech Poised for Rebound
… election of Donald Trump has buoyed the prospects of financials, energy and industrials. After an initial surge, health-care and biotech have not benefited nearly as much as other industries but definitely not as badly as utilities or consumer …
How CEOs Will Make The World A Better Place In 2017
Fast Company asked CEOs across industries-social good, sexual health, beauty, tech, and more-about how, in the face of uncertainty, they will seek to improve the world around us during the coming year. Here’s what they had to say.
article
… is more commonly known as Obamacare, has been a polarizing law since Day One. The Kaiser Family Foundation’s (KFF) Health Tracking Poll, which has been taken nearly every month since the ACA was signed into law in March 2010, often finds more people …
article
As 2016 comes to a close, it can arguably be described as the best year ever for marijuana. At the beginning of the year, 23 states had legalized medical cannabis, while residents in just four states had voted in favor of legalizing recreational marijuana.
5 Changes to Social Security in 2017
As 2017 draws near, there are several changes to Social Security that current and future beneficiaries should be aware of. While benefits aren’t increasing by too much, some workers could see their Social Security tax bill rise significantly, and working beneficiaries could end up with a lot more money in their pockets in 2017.
How to Get a Better Night’s Sleep
Most people know they need to eat right and exercise to be healthy. But what about sleep? We spend about one-third of our lives asleep, and sleep is essential to better health.
The Most Likely Incyte Acquisition Deal for 2017?
Could another acquisition involving Incyte be more likely, though? Here are some potential 2017 acquisition scenarios for Incyte: with Gilead, Agenus There are plenty of reasons why Gilead might want to buy Incyte next year. The big biotech has plenty of cash to spend.
The Most Likely Incyte Acquisition Deal for 2017?
Could another acquisition involving Incyte be more likely, though? Here are some potential 2017 acquisition scenarios for Incyte: with Gilead, Agenus There are plenty of reasons why Gilead might want to buy Incyte next year. The big biotech has plenty of cash to spend.
Are These 3 Stocks the Biggest Comeback Opportunities of 2017?
That’s good advice literally — and figuratively when it comes to buying stocks. You never know if a plunging stock will go down a lot more.
CalPERS to sell last $550 million worth of tobacco stocks
… managed by its in-house advisers, but it allowed outside managers to retain the investments they controlled. Public health organizations overwhelmingly opposed a re-investment, saying it would send the message that California supports a product that …
Gilead Sciences Has Bought Back $10 Billion of Stock in 2016. Should Investors Be Happy?
The stock has lost about 25% of its value in 2016, and management has taken advantage of the plunge by repurchasing about 100 million shares of its own stock. While it’s nice to know the shares were purchased at knockdown prices, it’s hard to remain cheerful when your stock price is sinking.
Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job
… or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email. For health care investors, CEO vacancies at two of the six big-cap biotech companies aren’t helping sentiment heading into 2017. The Dow …
Tax-Loss Selling: 3 Stocks to Dump Right Now
Tax-loss selling is an effective strategy to lower your tax bill. The basic idea is to sell stocks that have fallen on hard times and are unlikely to mount a comeback.
article
… can do about those costs. Healthcare costs for the average over-65 household is $5,756 per year, including $3,900 for health insurance and another $672 for drugs. If your costs are higher, make sure to adjust your spending projection upward. If …
Having a Baby in 2017? Here’s What You Need to Know
… in out-of-pocket medical costs during a child’s first year of life, but if you have a child with medical issues or a health plan with lackluster coverage, you could see that figure climb. Not only that, but you’ll need to add your child to your …